Nitric oxide synthase-inhibition hypertension is associated with altered endothelial cyclooxygenase function

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 287, Issue 6 56-6, 2004, Pages

  Bratz, Ian N ^a   Kanagy, Nancy L ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Endothelial cells; Norepinephrine; Vascular smooth muscle cells

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; NORADRENALIN; PROSTAGLANDIN SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HYPERTENSION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; SUPERIOR MESENTERIC ARTERY; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; BLOTTING, WESTERN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HYPERTENSION; ISOENZYMES; MALE; MEMBRANE PROTEINS; MESENTERIC ARTERIES; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; NITROARGININE; NITROBENZENES; NOREPINEPHRINE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; SALICYLATES; SULFONAMIDES; VASOCONSTRICTION;

EID: 9344268322     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00628.2004     Document Type: Article

References (49)

1. Auch-Schwelk W, Katusic ZS, and Vanhoutte PM. Thromboxane A2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension 15: 699-703, 1990.
2. Beverelli F, Bea ML, Puybasset L, Giudicelli JF, and Berdeaux A. Chronic inhibition of NO synthase enhances the production of prostacyclin in coronary arteries through upregulation of the cyclooxygenase type 1 isoform. Fundam Clin Pharmacol 11: 252-259, 1997.
3. Bouloumie A, Bauersachs J, Linz W, Scholkens BA, Wiemer G, Fleming I, and Busse R. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension 30: 934-941, 1997.
4. Bratz IN, Falcon R, Partridge LD and Kanagy NL. Vascular smooth muscle cell membrane depolarization after NOS inhibition hypertension. Am J Physiol Heart Circ Physiol 282: H1648-H1655, 2002.
5. Brovkovych V, Dobrucki LW, Brovkovych S, Dobrucki I, Do Nascimento CA, Burewicz A, and Malinski T. Nitric oxide release from normal and dysfunctional endothelium. J Physiol Pharmacol 50: 575-586, 1999.
6. Chang YW, Jakobi R, McGinty A, Foschi M, Dunn MJ, and Sorokin A. Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol Cell Biol 20: 8571-8579, 2000.
7. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, and Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107: 405-409, 2003.
8. Cheng HF, Wang JL, Zhang MZ, McKanna JA, and Harris RC. Nitric oxide regulates renal cortical cyclooxygenase-2 expression. Am J Physiol Renal Physiol 279: F122-F129, 2000.
9. Clancy R, Varenika B, Huang W, Ballou L, Attur M, Amin AR, and Abramson SB. Nitric oxide synthase/COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production. J Immunol 165: 1582-1587, 2000.
10. Cosentino F, Eto M, De Paolis P, van der LB, Bachschmid M, Ullrich V, Kouroedov A, Delli GC, Joch H, Volpe M, and Luscher TF. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 107: 1017-1023, 2003.
11. Da Cunha V, Rossoni LV, Oliveira PA, Poton S, Pretti SC, Vassallo DV, and Stefanen I. Cyclooxygenase inhibition reduces blood pressure elevation and vascular reactivity dysfunction caused by inhibition of nitric oxide synthase in rats. Clin Exp Hypertens 22: 203-215, 2000.
12. Darley-Usmar V, Wiseman H, and Halliwell B. Nitric oxide and oxygen radicals: a question of balance. FEBS Lett 369: 131-135, 1995.
13. De Artinano AA and Gonzalez VL. Endothelial dysfunction and hypertensive vasoconstriction. Pharmacol Res 40: 113-124, 1999.
14. Forster J, Beebe P, Wang H, and Wood JG. The effect of nitric oxide inhibition on blood pressure depends on rat strain. J Surg Res 96: 218-223, 2001.
15. Garcia-Cohen EC, Marin J, Diez-Picazo LD, Baena AB, Salaices M, and Rodriguez-Martinez MA. Oxidative stress induced by fert-butyl hydroperoxide causes vasoconstriction in the aorta from hypertensive and aged rats: role of cyclooxygenase-2 isoform. J Pharmacol Exp Ther 293: 75-81, 2000.
16. Godecke A, Decking UK, Ding Z, Hirchenhain J, Bidmon HJ, Godecke S, and Schrader J. Coronary hemodynamics in endothelial NO synthase knockout mice. Circ Res 82: 186-194, 1998.
17. Griendling KK, Sorescu D, Lassegue B, and Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 2175-2183, 2000.
18. Hajjar DP, Lander HM, Pearce SFA, Upmacis RK, and Pomerantz KB. Nitric oxide enhances prostaglandin-H synthase-1 activity by a heme-independent mechanism: evidence implicating nitrosothiols. J Am Chem Soc 117: 3340-3346, 1995.
19. Henrion D, Dechaux E, Dowell FJ, Maclour J, Samuel JL, Levy BI, and Michel JB. Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2. Br J Pharmacol 121: 83-90, 1997.
20. Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Luscher TF, and Ruschitzka F. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 108: 2308-2311, 2003.
21. Hirafuji M, Tsunoda M, Machida T, Hamaue N, Endo T, Miyamoto A, and Minami M. Reduced expressions of inducible nitric oxide synthase and cyclooxygenase-2 in vascular smooth muscle cells of stroke-prone spontaneously hypertensive rats. Life Sci 70: 917-926, 2002.
22. Huk I, Brovkovych V, Nanobash VJ, Weigel G, Neumayer C, Partyka L, Patton S, and Malinski T. Bioflavonoid quercetin scavenges superoxide and increases nitric oxide concentration in ischaemia-reperfusion injury: an experimental study. Br J Surg 85: 1080-1085, 1998.
23. 2- adrenergic stimulation during NOS inhibition-induced hypertension. Am J Physiol Heart Circ Physiol 273: H2756-H2764, 1997.
24. Kato T, Iwama Y, Okumura K, Hashimoto H, Ito T, and Satake T. Prostaglandin H2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 15: 475-481, 1990.
25. Katusic ZS, Schugel J, Cosentino F, and Vanhoutte PM. Endothelium-dependent contractions to oxygen-derived free radicals in the canine basilar artery. Am J Physiol Heart Circ Physiol 264: H859-H864, 1993.
26. Kishi K and Inoue T. Possible mechanisms of abnormal norepinephrine sensitivity and reactivity of resistance vessels and the development of hypertension in spontaneously hypertensive rats. A hypothesis. Am J Hypertens 3: 202S-205S, 1990.
27. Kumar R, Joyner RW, Hartzell HC, Ellingsen D, Rishi F, Eaton DC, Lu C, and Akita T. Postnatal changes in the G-proteins, cyclic nucleotides and adenylyl cyclase activity in rabbit heart cells. J Mol Cell Cardiol 26: 1537-1550, 1994.
28. Laemmel E, Bonnardel-Phu E, Hou X, Seror J, and Vicaut E. Interaction between nitric oxide and prostanoids in arterioles of rat cremaster muscle in vivo. Am J Physiol Heart Circ Physiol 285: H1254-H1260, 2003.
29. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, and Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201-1209, 2003.
30. Llinas MT, Rodriguez F, Moreno C, and Salazar FJ. Role of cyclooxygenase-2-derived metabolites and nitric oxide in regulating renal function. Am J Physiol Regul Integr Camp Physiol 279: R1641-R1646, 2000.
31. Macedo MP and Lautt WW. Potentiation to vasodilators by nitric oxide synthase blockade in superior mesenteric but not hepatic artery. Am J Physiol Gastrointest Liver Physiol 272: G507-G514, 1997.
32. Maffei A, Poulet R, Vecchione C, Colella S, Fratta L, Frati G, Trimarco V, Trimarco B, and Lembo G. Increased basal nitric oxide release despite enhanced free radical production in hypertension. J Hypertens 20: 1135-1142, 2002.
33. Marcelin-Jimenez G and Escalante B. Functional and cellular interactions between nitric oxide and prostacyclin. Camp Biochem Physiol C Toxicol Pharmacol 129: 349-359, 2001.
34. Meng W, Ayata C, Waeber C, Huang PL, and Moskowitz MA. Neuronal NOS-cGMP-dependent ACh-induced relaxation in pial arterioles of endothelial NOS knockout mice. Am J Physiol Heart Circ Physiol 274: H411-H415, 1998.
35. Millgard J and Lind L. Acute hypertension impairs endothelium-dependent vasodilation. Clin Sci (Lond) 94: 601-607, 1998.
36. Moreau P, Takase H, Kung CF, Shaw S, and Luscher TF. Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension 29: 763-769, 1997.
37. Numaguchi Y, Harada M, Osanai H, Hayashi K, Toki Y, Okumura K, Ito T, and Hayakawa T. Altered gene expression of prostacyclin synthase and prostacyclin receptor in the thoracic aorta of spontaneously hypertensive rats. Cardiovasc Res 41: 682-688, 1999.
38. Quinn S, O'Brien C, and McLoughlin P. Role of cyclooxygenase and haemoxygenase products in nitric oxide-independent vasodilatation in the porcine ciliary artery. Eye 17: 628-636, 2003.
39. Rathaus M and Bernheim J. Oxygen species in the microvascular environment: regulation of vascular tone and the development of hypertension. Nephrol Dial Transplant 17: 216-221, 2002.
40. Sedeek MH, Llinas MT, Drummond H, Fortepiani L, Abram SR, Alexander BT, Reckelhoff JF, and Granger JP. Role of reactive oxygen species in endothelin-induced hypertension. Hypertension 42: 806-810, 2003.
41. Steudel W, Ichinose F, Huang PL, Hurford WE, Jones RC, Bevan JA, Fishman MC, and Zapol WM. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res 81: 34-41, 1997.
42. Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, and Salvetti A. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 38: 274-279, 2001.
43. Taddei S, Virdis A, Ghiadoni L, Sudano I, and Salvetti A. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 38, Suppl 2: S11-S14, 2001.
44. Tomida T, Numaguchi Y, Nishimoto Y, Tsuzuki M, Hayashi Y, Imai H, Matsui H, and Okumura K. Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2α formation in L-NAME-treated rats. J Hypertens 21: 601-609, 2003.
45. Vassalle C, Domenici C, Lubrano V, and L'Abbate A. Interaction between nitric oxide and cyclooxygenase pathways in endothelial cells. J Vasc Res 40: 491-499, 2003.
46. Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney JF Jr, Morrow JD and Vita JA. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42: 310-315, 2003.
47. Wigg SJ, Tare M, Tonta MA, O'Brien RC, Meredith IT, and Parkington HC. Comparison of effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery. Am J Physiol Heart Circ Physiol 281: H232-H240, 2001.
48. Yang X, Sheares KK, Davie N, Upton PD, Taylor GW, Horsley J, Wharton J, and Morrell NW. Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 27: 688-696, 2002.
49. Zapolska-Downar D, Zapolska-Downar A, Bukowska H, Galka H, and Naruszewicz M. Ibuprofen protects low density lipoproteins against oxidative modification. Life Sci 65: 2289-2303, 1999.